SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
View / Open Files
Authors
Collier, Dami A
De Marco, Anna
Ferreira, Isabella ATM
Meng, Bo
Walls, Alexandra C
Kemp S, Steven A
Bassi, Jessica
Pinto, Dora
Fregni, Chiara Silacci
Bianchi, Siro
Tortorici, M Alejandra
Bowen, John
Culap, Katja
Jaconi, Stefano
Cameroni, Elisabetta
Snell, Gyorgy
Pizzuto, Matteo S
Pellanda, Alessandra Franzetti
Garzoni, Christian
Riva, Agostino
CITIID-NIHR BioResource COVID-19 Collaboration
Elmer, Anne
Kingston, Nathalie
Graves, Barbara
McCoy, Laura E
Smith, Kenneth Gc
Bradley, John R
Temperton, Nigel
Ceron-Gutierrez L, Lourdes
Barcenas-Morales, Gabriela
COVID-19 Genomics UK (COG-UK) consortium
Harvey, William
Virgin, Herbert W
Lanzavecchia, Antonio
Piccoli, Luca
Doffinger, Rainer
Veesler, David
Corti, Davide
Gupta, Ravindra K
Publication Date
2021-02-15Journal Title
Nature
ISSN
0028-0836
Publisher
Nature Research
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Collier, D. A., De Marco, A., Ferreira, I. A., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., et al. (2021). SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.. Nature https://doi.org/10.1038/s41586-021-03412-7
Abstract
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.
Keywords
The CITIID-NIHR BioResource COVID-19 Collaboration, The COVID-19 Genomics UK (COG-UK) consortium
Sponsorship
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC 2017-22)
Identifiers
External DOI: https://doi.org/10.1038/s41586-021-03412-7
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334736
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.